IP Library Granted Patent US 12,098,365
Granted Patent B2
US 12,098,365 · App. 17/213,611 · Granted Sep 24, 2024

Modified mammalian cells

Inventors: Michael Wilson Laird (South San Francisco, CA); Shahram Misaghi (South San Francisco, CA); Amy Shen (South San Francisco, CA); Anthony Tomlinson (South San Francisco, CA); Inn Huam Yuk (South San Francisco, CA)
Assignee: GENENTECH, INC.
C12N15/102C12N5/0682C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,365
App. No.
17/213,611
Granted
Sep 24, 2024
Kind
B2
Abstract

The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.

Claims (17)

1. A recombinant host cell, wherein the cell is modified to reduce or eliminate the activity of a plurality of enzymes relative to the activity of the enzymes in an unmodified cell, wherein the enzymes are Phospholipase A2 group XV (LPLA2); Lipoprotein lipase (LPL); Lipase A (Lysosomal acid lipase ester hydrolase, Lipase) (LIPA); Palmitoyl-protein thioesterase 1 (PPT1); phospholipase B-domain containing 2 (PLBL2 PLBD2); Phospholipase D3 (PLD3); and Sphingomyelin phosphodiesterase (SMPD1).

2. The recombinant host cell of claim 1 , wherein the activity of the enzymes is reduced or eliminated by:

a. knocking down expression of the enzymes;

h. or knocking out expression of the enzymes; or

c. altering the nucleic acid sequence encoding the enzymes.

3. The recombinant host cell of claim 1 , wherein the cell comprises a plurality of altered enzyme genes.

4. The recombinant host cell of claim 3 , wherein the altered enzyme genes have no detectable enzymatic activity.

5. The recombinant host cell of claim 1 , wherein the cell is a mammalian cell.

6. The recombinant host cell of claim 5 , wherein the cell is a CHO cell.

7. The recombinant host cell of claim 1 , comprising a nucleic acid sequence encoding a product of interest.

8. The recombinant host cell of claim 7 , wherein the product of interest comprises a protein, a viral particle or a viral vector.

9. The recombinant host cell of claim 7 , wherein the product of interest comprises a recombinant protein.

10. The recombinant host cell of claim 7 , wherein the product of interest comprises an antibody or an antigen-binding fragment thereof.

11. The recombinant host cell of claim 7 , wherein the nucleic acid sequence is integrated in the cellular genome of the mammalian cell at a targeted location.

12. The recombinant host cell of claim 11 , further comprising a second nucleic acid sequence encoding the product of interest, which is randomly integrated in the cellular genome of the mammalian cell.

13. The recombinant host cell of claim 1 , wherein the modified cell does not express any detectable LPL; PLBL2/PLBD2; LIPA; PLD3; LPLA2.

14. A composition comprising a recombinant host cell of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2021
From: LAIRD, MICHAEL WILSON; MISAGHI, SHAHRAM; SHEN, AMY; YUK, INN HUAM
To: GENENTECH, INC.
Reel/Frame 056250/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2021
From: TOMLINSON, ANTHONY
To: GENENTECH, INC.
Reel/Frame 056251/0023 →
Continuity (4)
Provisional Application 63155225 · Mar 1, 2021
Provisional Application 63128419 · Dec 21, 2020
Provisional Application 63000464 · Mar 26, 2020
Related Publication 20210309989A1 · Oct 7, 2021